Svar Life Science

July 2, 2025

Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

As gene therapy continues to revolutionize modern medicine, the need for robust, scalable tools to evaluate vector performance and immune responses has never been greater. One critical challenge in this field is the detection of neutralizing antibodies (NAbs) against adeno-associated virus (AAV) vectors, which can significantly impact the efficacy of gene delivery.

Svar Life Science addresses this challenge with its innovative iLite AAV Nab assay platform - a powerful solution designed to streamline and standardize NAb detection across various AAV serotypes, including both established wildtypes as well as recombinant versions.

July 2, 2025

Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

As gene therapy continues to revolutionize modern medicine, the need for robust, scalable tools to evaluate vector performance and immune responses has never been greater. One critical challenge in this field is the detection of neutralizing antibodies (NAbs) against adeno-associated virus (AAV) vectors, which can significantly impact the efficacy of gene delivery.

Svar Life Science addresses this challenge with its innovative iLite AAV Nab assay platform - a powerful solution designed to streamline and standardize NAb detection across various AAV serotypes, including both established wildtypes as well as recombinant versions.

What Are iLite AAV Nab Assay Platform?

This is a dual cell system with a luminescence-based reporter cell line and assay-ready packaging cells engineered to efficiently produce your vectors of choice. Optimized to work together, they offer a quantitative, reproducible, and high-throughput method for assessing vector functionality and immune interference.

Why It Matters for NAb Detection

Neutralizing antibodies can block AAV-mediated gene delivery, posing a major hurdle in both preclinical and clinical settings. The iLite system enables researchers to:

  • Quantify NAb activity with high sensitivity and specificity
  • Compare immune responses across different AAV serotypes
  • Support regulatory submissions with standardized, reproducible data

Key Benefit

  • Assay-Ready Format: No culturing required-just thaw and use
  • High Sensitivity: Luminescent readout ensures precise quantification
  • Versatile Applications: Ideal for NAb screening, vector potency testing, and assay development
  • Batch-to-Batch Consistency: Manufactured under stringent quality controls
  • Scalable for High-Throughput: Suitable for academic labs, CROs, and biotech companies

AAV9 as a Leading Example

Among the AAV serotypes, AAV9 is particularly prominent due to its ability to cross the blood-brain barrier and target muscle and CNS tissues. iLite AAV9 Packaging Assay Ready Cells are specifically tailored for this serotype, making them an ideal choice for researchers developing therapies for neurological and neuromuscular disorders.
Who Should Use This?

Whether you're a scientist exploring new gene therapy vectors, a CRO validating immune responses, or a biotech company optimizing delivery platforms, iLite Assay Ready Cells provide the flexibility and reliability needed to accelerate your research.

 

Empower your gene therapy pipeline with tools designed for precision and performance.